Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in advanced/metastatic/unresectable melanoma; study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• IO102-IO103 (IO102-IO103)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: IO Biotech | Conditions: Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING